secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001193125-25-168830
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA
-----------------------------------------------------------------------------

- Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.
- Standby Equity Purchase Agreement: up to $15M over 36 months; shares sold at 96% of lowest 3-day VWAP.
- Floor price set at $0.28 per share; Yorkville may require share issuance at lower of 115% of VWAP or 95% of lowest 7-day VWAP.
- Commitment fee of $300k paid as 213,099 shares plus $25k structuring fees; Exchange Cap limited to 19.9% of outstanding shares.
- Proceeds used for general corporate purposes; shares registered on Form S-3 (File No. 333-287342).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525168830/0001193125-25-168830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525168830/d56953d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-168830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer